# Nai-Kong V. Cheung

Source: https://onco.cc/people/nai-kong-cheung/  
OnCo record `nai-kong-cheung` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Developed the anti-GD2 antibodies 3F8 and naxitamab that treat relapsed neuroblastoma.

## Summary

Nai-Kong Cheung developed the murine anti-GD2 antibody 3F8 in the 1980s and its humanised successor naxitamab, which won FDA approval in 2020 for relapsed or refractory high-risk neuroblastoma in bone or bone marrow, and has led decades of MSKCC trials of antibody-based immunotherapy in children. His laboratory engineers bispecific antibodies and CAR T cells against GD2 and other paediatric targets.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: paediatric; neuroblastoma; immunotherapy
- Role: Enid A. Haupt Chair in Pediatric Oncology, Memorial Sloan Kettering Cancer Center
- Specialisms: Neuroblastoma; Anti-GD2 antibodies; Paediatric immunotherapy; Antibody engineering

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Cheung%20NK%5BAuthor%5D%20neuroblastoma%20GD2

## Connected records

- cancers: [Neuroblastoma (paediatric)](https://onco.cc/cancers/neuroblastoma/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- institutions: [Memorial Sloan Kettering Cancer Center](https://onco.cc/institutions/mskcc/)
- trials: [Naxitamab Study 201](https://onco.cc/trials/naxitamab-201/)

---
JSON: https://onco.cc/api/v1/entities/nai-kong-cheung.json